We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $13.67 · 3 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release Stockhouse
Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Price Today & Analysis - Gotrade
Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Price Today & Analysis Gotrade
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out ACCESS Newswire
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) ChartMill
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.35 | — | — | $50K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $3.5 | — | — | $98.15M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-11.34 | — | — | $96.19M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-8.64 | — | — | $56M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 19. | Freedom Broker | — | Upgrade | Sell → Hold | — | Freedom Broker: Sell → Hold |
| 2026. 05. 09. | Canaccord Genuity | — | Upgrade | Hold → Buy | — | Canaccord Genuity: Hold → Buy |
| 2026. 01. 21. | Freedom Broker | — | Downgrade | Buy → Sell | — | Freedom Broker: Buy → Sell |
| 2026. 01. 14. | Canaccord Genuity | — | Downgrade | Buy → Hold | — | Canaccord Genuity: Buy → Hold |
| 2025. 12. 20. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
| 2025. 03. 11. | Canaccord Genuity | — | Maintain | Buy → Buy | — | Canaccord Genuity: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 194,264 | $918.87M | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 18,296 | $330.98M | 0.00% | — | New position |